The genetic understanding of cancer has led to enhanced individual risk assessment, improved screening guidelines, and improved outcomes based on cancer prevention, early detection, and, in some cases, targeted therapy. Huntsman Cancer Institute (HCI) is positioned to make exceptional contributions in this individualized oncology arena. HCI has a unique research resource to support genetic and population studies, the Utah Population Database (UPDB), a compelling history of genetic discovery in oncology, and a strategic plan to accelerate translational advances from this platform. We have forged an alliance with Intermountain Healthcare, a nationally acclaimed Utah health network, linking data for more than 80-85 percent of the cancer patients in our State to the UPDB, enabling the entire population of Utah to comprise a cancer research laboratory for genetic, population, and outcomes research. Utah is home to seven Native American tribes or nations as well as extensive rural and frontier populations that have poor cancer outcomes.
We aim to serve as a national research resource for addressing the needs of these underserved populations to improve cancer prevention and care. HCI research is organized into five Programs that provide an environment of cancer focus, transdisciplinary exchange, and collaboration: Nuclear Control of Cell Growth and Differentiation;Cell Response and Regulation;Imaging, Diagnostics, and Therapeutics;Gastrointestinal Cancers;and Cancer Control and Population Sciences. These Programs integrate the activities of 133 members who have $45 million in extramural grant support, with more than $17 million in NCI direct costs. Cancer-focused research during the current award period is documented in 1,374 unique publications, of which 26 percent are collaborative with one or more Cancer Center members. Thirteen Cancer Center Shared Resources support our scientists, providing access to specialized instrumentation, assays, services, research materials, and expert consultation and collaboration. We request funds to support Years 21-25 of our Cancer Center Support Grant (CCSG). A new Executive Director, Mary Beckerle, Ph.D., was appointed in August 2006. Under her leadership, HCI has developed a plan to guide the next five years, including expansion of HCI's cancer specialty hospital, expansion of HCI's genetic platform for pre-clinical studies, development of a Center for Investigational Therapeutics (including a Phase I program), and expansion of population science (including epidemiological and behavioral research) to impact care of cancer survivors and reduce health disparities.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA042014-23S1
Application #
8533380
Study Section
Subcommittee G - Education (NCI)
Program Officer
Ptak, Krzysztof
Project Start
1997-05-09
Project End
2015-04-30
Budget Start
2012-05-01
Budget End
2013-04-30
Support Year
23
Fiscal Year
2012
Total Cost
$75,000
Indirect Cost
$24,833
Name
University of Utah
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
009095365
City
Salt Lake City
State
UT
Country
United States
Zip Code
84112
Zeng, Tao; Fleming, Aaron M; Ding, Yun et al. (2018) Nanopore Analysis of the 5-Guanidinohydantoin to Iminoallantoin Isomerization in Duplex DNA. J Org Chem 83:3973-3978
Himbert, Caroline; Ose, Jennifer; Nattenmüller, Johanna et al. (2018) Body fatness, adipose tissue compartments and biomarkers of inflammation and angiogenesis in colorectal cancer: the ColoCare Study. Cancer Epidemiol Biomarkers Prev :
Madison, Bethany J; Clark, Kathleen A; Bhachech, Niraja et al. (2018) Electrostatic repulsion causes anticooperative DNA binding between tumor suppressor ETS transcription factors and JUN-FOS at composite DNA sites. J Biol Chem 293:18624-18635
Arbeeva, Liubov S; Hanson, Heidi A; Arbeev, Konstantin G et al. (2018) How Well Does the Family Longevity Selection Score Work: A Validation Test Using the Utah Population Database. Front Public Health 6:277
Patel, Ami B; Lange, Thoralf; Pomicter, Anthony D et al. (2018) Similar expression profiles in CD34+ cells from chronic phase chronic myeloid leukemia patients with and without deep molecular responses to nilotinib. Oncotarget 9:17889-17894
De, Shrutokirti; Van Deren, Donn; Peden, Eric et al. (2018) Two distinct ontogenies confer heterogeneity to mouse brain microglia. Development 145:
Giraddi, Rajshekhar R; Chung, Chi-Yeh; Heinz, Richard E et al. (2018) Single-Cell Transcriptomes Distinguish Stem Cell State Changes and Lineage Specification Programs in Early Mammary Gland Development. Cell Rep 24:1653-1666.e7
Doherty, Jennifer A; Grieshober, Laurie; Houck, John R et al. (2018) Telomere Length and Lung Cancer Mortality among Heavy Smokers. Cancer Epidemiol Biomarkers Prev 27:829-837
Wagner, Alex H; Devarakonda, Siddhartha; Skidmore, Zachary L et al. (2018) Recurrent WNT pathway alterations are frequent in relapsed small cell lung cancer. Nat Commun 9:3787
Kleinstern, Geffen; Camp, Nicola J; Goldin, Lynn R et al. (2018) Association of polygenic risk score with the risk of chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis. Blood 131:2541-2551

Showing the most recent 10 out of 1193 publications